SCHEMBL2292297

SCHEMBL2292297

O=C(Nc1ccccc1C(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNK2 O95069 1/20 0.62
KCNK10 P57789 1/20 0.62
MEN1 O00255 1/20 0.61
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
DHODH Q02127 1/20 0.59
SERPINE1 P05121 1/20 0.58
RXFP1 Q9HBX9 2/20 0.57
PTGS1 P23219 1/20 0.57
MAPK14 Q16539 1/20 0.56
TRPA1 O75762 1/20 0.55
TRPM8 Q7Z2W7 1/20 0.55
IGF2BP2 Q9Y6M1 1/20 0.55
PLK1 P53350 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466712 0.90 MEN1 (0.72) KCNK2KCNK10MEN1NPC1RAB9A
SCHEMBL2025586 0.90 MEN1 (0.72) KCNK2KCNK10MEN1NPC1RAB9A
SCHEMBL2292518 0.89 SERPINE1 (0.71) KCNK2KCNK10MEN1NPC1RAB9A
SCHEMBL2275706 0.89 SERPINE1 (0.58) KCNK2KCNK10NPC1RAB9AKMT2A
SCHEMBL2272432 0.87 PYGL (0.55) KCNK2KCNK10MEN1NPC1RAB9A
SCHEMBL2293270 0.87 SERPINE1 (0.70) KCNK2KCNK10SERPINE1RXFP1MAPK14
SCHEMBL2295612 0.86 CYP1A2 (0.64) KCNK2KCNK10MEN1NPC1RAB9A
SCHEMBL8027764 0.86 MEN1 (0.67) KCNK2KCNK10MEN1NPC1RAB9A
SCHEMBL2292286 0.84 MEN1 (0.64) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL2293960 0.84 SERPINE1 (0.76) MEN1NPC1RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 KCNK2 3279/4885KCNK10 2741/4885MEN1 1329/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 KCNK2 2982/4885KCNK10 2421/4885MEN1 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.